» Articles » PMID: 22691888

Pheochromocytoma: Implications in Tumorigenesis and the Actual Management

Overview
Specialty Endocrinology
Date 2012 Jun 14
PMID 22691888
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Pheochromocytomas and paragangliomas are rare neuroendocrine catecholamine producing tumors with varied clinical presentations, biochemistries and genetic makeup. These features outline the complexity and the difficulties in studying and understanding the oncogenesis of these tumors. The study of families with genetically inherited mutations in pheochromocytoma susceptibility genes has greatly enhanced our understanding of the pathophysiology and mechanisms of oncogenesis of the disease, and consequently changed our clinical approach. Several molecular pathways and mutations in their important regulatory proteins have been identified. Such mutations are responsible for the dysregulation of metabolic pathways involved in oxygen and nutrient sensing, apoptosis regulation, cell proliferation, migration and invasion. The knowledge derived from the study of these pathways will be fundamental in the future clinical management of these patients. As a rare disease that often masks its clinical presentation, the diagnosis is frequently missed and a high level of suspicion is required. Management of this disease requires a multidisciplinary team approach and will be discussed along with advances in its treatment.

Citing Articles

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.

Grand-Guillaume J, Mansi R, Gaonkar R, Zanger S, Fani M, Eugster P J Transl Med. 2023; 21(1):604.

PMID: 37679770 PMC: 10485979. DOI: 10.1186/s12967-023-04466-z.


Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives.

Sobocki B, Perdyan A, Szot O, Rutkowski J J Clin Med. 2022; 11(9).

PMID: 35566714 PMC: 9103340. DOI: 10.3390/jcm11092591.


Therapies targeting the signal pathways of pheochromocytoma and paraganglioma.

Liu Y, Liu L, Zhu F Onco Targets Ther. 2019; 12:7227-7241.

PMID: 31564906 PMC: 6732510. DOI: 10.2147/OTT.S219056.


Rare complications of neurofibromatosis 1 diagnosed incidentally in two children.

Lazea C, Asavoaie C, Al-Khzouz C, Popa L Ther Clin Risk Manag. 2018; 14:1547-1552.

PMID: 30214218 PMC: 6124468. DOI: 10.2147/TCRM.S173237.


Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Osinga T, Links T, Dullaart R, Pacak K, van der Horst-Schrivers A, Kerstens M FASEB J. 2017; 31(6):2226-2240.

PMID: 28264974 PMC: 5434646. DOI: 10.1096/fj.201601131R.


References
1.
Qin Y, Buddavarapu K, Dahia P . Pheochromocytomas: from genetic diversity to new paradigms. Horm Metab Res. 2009; 41(9):664-71. DOI: 10.1055/s-0029-1215590. View

2.
Colson P, Ribstein J . [Simplified strategy for anesthesia of pheochromocytoma]. Ann Fr Anesth Reanim. 1991; 10(5):456-62. DOI: 10.1016/s0750-7658(05)80849-4. View

3.
van Nederveen F, Gaal J, Favier J, Korpershoek E, Oldenburg R, de Bruyn E . An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009; 10(8):764-71. PMC: 4718191. DOI: 10.1016/S1470-2045(09)70164-0. View

4.
Pacak K . Phaeochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul. 2011; 45(2):65-90. PMC: 3414427. DOI: 10.4149/endo_2011_02_65. View

5.
Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R . Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003; 88(11):5150-7. DOI: 10.1210/jc.2003-030262. View